7Fumoleau P, Largillier R, Clippe C,et al. Multieentre,phase Ⅱ study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer [J]. Eur J Cancer,2004,40 (4) :536.
8Verma S, Ilersich A L. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer [J]. Oncologlst,2003,8 (3) : 232.
2[1]Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efiicacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res, 1998, 4 (4) :1013
3[2]Tsuchida Y, Therasse P. Response evaluation criteria in solid tumors (RECIST): New guidelines. Med Pediatr Oncol, 2001,37 (1) :1
4[4]Jones S, Erban J, Overmoyer B, et al. Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. The 26th Annual SanAntonio Breast Cancer Symposium,2003 (abstract 10)
5[6]Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol, 2000, 45(4):291
6[8]George W Sledge, Donna Neuberg, Patricia Bemardo, et al.Phase Ⅲ trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front- line chemotherapy for metastatic breast cancer: An Intergroup Trial (El193). J Clin Oncol, 2003, 21 (4) :588
7[9]Alba E, Martin M, Ramos M, et al. Multicenter phase randomized trial comparing sequential versus concomitant administration of doxorubicin (A) and docetaxel (T) as first- line treatment of metastatic breast cancer (MBC). GEICAM 9903 Study.ASCO, 2003, 22: 8 (abstract 27)
8[10]O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer:Phase Ⅲ trial results. J Clin Oncol, 2002, 20 (12) :2812
9[11]London Susan Mayor. NICE recommends new treatment for breast and bowel cancer. BMJ, 2003, 326:1166
10[12]Jiang Z, Liu F, Song S, et al. HER-2 overexpression predicts better reponse to taxane chemotherapy in patients with advanced breast cancer. Breast Cancer Research and Treatment,2003, Vol 82 (Suppl), S72. The 26th Annual SanAntonio Breast Cancer Symposium 2003 (abstract 312)
